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Travel and Migration Medicine Unit, Department of Community Medicine,
Geneva University Hospital, Geneva
We describe a 21-year-old patient who experienced a relapse
of cutaneous gnathostomiasis after receiving initial treatment
with albendazole and who had a successful outcome after
receiving a short course of ivermectin for the relapse. This
is the first reported case of gnathostomiasis acquired by a
human in Peru.
A 21-year-old woman of Peruvian origin visited her family in
Peru for 5 weeks in 1999. During the 3 years prior to her visit
to Peru, she had lived in Geneva, Switzerland. The patient was
based in Lima while in Peru, but she traveled to Huraz, located
in central Peru, for a 5-day stay. One week before her return
to Switzerland, while she was staying in Huraz, she presented
with epigastric pain, watery diarrhea, nausea, and anorexia, all
of 4 days’ duration. Five days later (day 0), she noted pruritic
swelling on the left side of the groin and used an antihistaminic
ointment to treat it. The swelling spontaneously resolved by
day 5, but a second area of swelling, which appeared on the
inner left thigh on day 9, lasted for a few days. The subcuta-
neous swelling subsequently migrated toward the inner left knee
on day 13, followed by migration to the outer left knee on day
16 and to the top of the outer left thigh on day 19 (figure 1).
The patient was examined in a district hospital on day 20 and
was referred to us on day 22.
The patient complained of general itching, fatigue, and
headache. She did not complain of other neurological symp-
toms or fever. Physical examination revealed a subcutaneous
and cutaneous tumefaction located on the outer, left mid-
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thigh. There were no other skin lesions, and the lymph nodes
were not enlarged. The patient’s vital signs were within nor-
mal limits, as were the results of the rest of the physical
examination. A complete blood count showed normal RBC
values but an absolute eosinophil count of 2700 cells/mm3
(31% of 8900 WBCs/mm3). Her platelet count was slightly
elevated (386,000 cells/mm3). The erythrocyte sedimentation
rate and levels of C-reactive protein, electrolytes, blood urea
nitrogen, creatinine, aspartate aminotransferase, alanine ami-
notransferase, bilirubin, and creatine kinase all were within
normal limits. Serologic tests for parasitic diseases were per-
formed.
A more thorough history of the patient’s travel experiences
revealed that she had eaten ceviche (a very popular dish made
of raw fish marinated in lime juice) on a daily basis. Different
species of saltwater or freshwater fish can be used in the prep-
aration of the dish. The patient denied having consumed any
other raw or improperly cooked food.
Despite the absence in the literature of reported cases of
gnathostomiasis in humans in Peru, clinical suspicion of gna-
thostomiasis was strong enough for the patient to start receiv-
ing, on day 22, albendazole, 400 mg b.i.d. for 3 weeks. The
swelling migrated down to the popliteal area of the left knee
on day 25 and did not reappear while the patient received
albendazole therapy. The eosinophil count decreased to 165
cells/mm3 by the end of treatment. Results of serologic tests
performed at Mahidol University in Bangkok, Thailand, con-
firmed the diagnosis of gnathostomiasis, by use of an indirect
ELISA that detected specific antibodies to a purified 24-kDa
antigen obtained from advanced third-stage larvae of Gna-
thostoma spinigerum. In Thailand, this test has been reported
to be 100% sensitive and 100% specific [1] for the detection
of gnathostomiasis. Results of serologic tests for paragonimiasis,
fascioliasis, toxocariasis, filariasis, strongyloidiasis, and cysti-
cercosis were all negative. Results of 3 stool sample examina-
tions were also negative.
The patient had no symptoms until 12 weeks after the end
of albendazole therapy (day 60), when an 8-cm  5-cm cu-
taneous inflammatory plaque reappeared on her inner left knee.
Her eosinophil count was 150 cells/mm3. Ivermectin, 12 mg
(200 mg/kg)/day, was then given for 2 consecutive days. There
were no side effects, and there were no signs of relapse at the
12-month follow-up. The patient can be considered cured.
Human gnathostomiasis, a disease that is endemic in South-
east Asia, is most frequently caused by G. spinigerum. It is
acquired as a result of ingestion of encysted larvae in the flesh
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Figure 1. Migration of the subcutaneous swelling on the left lower
limb.
of undercooked fish, poultry, frogs, and many other animals.
Most cases have been reported from Thailand and Japan. The
disease is due to the migration of the third-stage larvae. It most
frequently affects the skin and subcutaneous tissue, but larvae
can migrate to the vital organs, including the CNS, lungs, and
eyes, and the disease can be fatal [2]. The first case of gna-
thostomiasis in humans in Latin America was reported in Mex-
ico in 1970 [3]. Since then, 11000 cases have been identified
in Mexico [4–6]. Most cases have been related to the con-
sumption of raw freshwater fish (especially tilapia) prepared as
ceviche, a custom that began after the construction of dams
and reservoirs and the introduction of tilapia in artificial fresh-
water lakes in 1964. Lime juice is ineffective in killing the larvae,
even when the fish have been marinated in the lime juice at
room temperature for several days. In South America, gna-
thostomiasis in humans has been reported in Ecuador [7], with
sporadic cases seeming to have occurred in Peru as well (E.
Gotuzzo, personal communication).
The specific chemotherapy used for the treatment of patients
with gnathostomiasis relies on high-dose albendazole therapy
given for 3 weeks; rates of cure (i.e., absence of recurrence)
that are as high as 94% have been reported at 6 months after
initiation of treatment [8]. Ivermectin, an avermectin B deriv-
ative, is effective against several nematodes in the larval stages
(i.e., Oncocerca volvulus and Ancylostoma species that cause
cutaneous larva migrans) as well as the adult stage (i.e., Stron-
gyloides stercoralis and Ascaris lombricoides). Ivermectin was also
efficacious in rabbits that were experimentally infected with
third-stage larvae of G. spinigerum [9]. A relapse of a case of
cutaneous gnathostomiasis in a human recently was reported
to have relapsed after 2 consecutive doses of ivermectin, 200
mg/kg, were given [10]. Albendazole was effective in markedly
reducing the eosinophil count in our patient, but it did not
prevent a relapse of swelling. This raises a question regarding
the nature of this relapse that occurred 17 days after the com-
pletion of albendazole treatment. Although the relapse is
thought to be related to the presence of the migrating larva,
we cannot rule out the possibility that it is related to a local
reaction caused by the spontaneous death of the parasite. Since
the completion of the 2-day course of ivermectin, no relapses
have occurred, which suggests some efficacy of ivermectin.
In summary, we describe the first report of gnathostomiasis
in a human in Peru, including the successful outcome pro-
vided by a short course of ivermectin. Gnathostomiasis is a
potentially serious infection that is acquired by ingestion of
raw fish, which is a well-known source of several other par-
asitic diseases (i.e., anisakiasis, clonorchiasis, and opistor-
chiasis); travelers may be particularly at risk. In view of this
case, the epidemiologic findings regarding gnathostomiasis
should be studied further in Peru. Moreover, additional re-
search regarding the efficacy of ivermectin for the treatment of
individuals from different areas of endemicity would be worth-
while, considering the excellent tolerance for the drug, its short
2-day treatment schedule, and the expectation of better patient
compliance with the regimen.
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